LABA/LAMA Fixed-Dose Combinations Will Emerge and Capture More Than 33 Percent of the COPD Market in 2021, According to Findings from Decision Resources
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured as several new agents reach the market over the next decade. Two maintenance therapies currently dominate the COPD market—Boehringer Ingelheim/Pfizer’s Spiriva and GlaxoSmithKline’s Advair/Seretide/Adoair. In 2011, combined sales of these therapies constituted nearly two-thirds of the COPD market. As new therapies launch, they will erode the dominance of Advair/Seretide/Adoair and Spiriva and combined market share of these two agents will fall to 12 percent in 2021.
The Pharmacor advisory service entitled Chronic Obstructive Pulmonary Disease finds that the market for COPD will increase from nearly $9 billion in 2011 to $13.3 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Growth in the market will be in part driven by uptake of a new drug class—fixed-dose combination inhalers containing a long-acting beta2 agonist (LABA) and a long-acting muscarinic antagonist (LAMA)—that will launch in 2014 and offer more potent bronchodilation than currently available treatments. In 2019, LABA/LAMA combinations are expected to become the sales-leading drug class in COPD and in 2021 they will capture more than 33 percent of the market share.
“Advair and Spiriva have dominated COPD treatment for a number of years and although they will still be widely used, most interviewed experts are excited about LABA/LAMAs,” said Decision Resources Analyst Amanda Puffer. “Thought leaders expect to use these combinations in COPD patients of all severities and think they will have a significant impact on the treatment algorithm.”
The findings also reveal that expiry of patents and market exclusivities for many of the top-selling drugs will constrain the market, as lower-priced branded generic or generic versions become available. The uptake of lower-priced versions will contribute to the erosion of both Advair/Seretide/Adoair’s and Spiriva’s market dominance.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Christopher Comfort, 781-993-2597
Source: Decision Resources